CRESCENT BIOPHARMA, INC. Operating Lease, Payments
CRESCENT BIOPHARMA, INC. (CBIO) reported Operating Lease, Payments of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-26
- CRESCENT BIOPHARMA, INC. operating lease, payments for the quarter ending 2025-03-31 was $67.40K, a 65.67% decline year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, payments for the quarter ending 2024-12-31 was $200.24K, a 16.12% increase year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, payments for the quarter ending 2024-09-30 was $196.31K, a 31.15% decline year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, payments for the quarter ending 2024-06-30 was $196.31K, a 30.02% decline year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, payments for fiscal 2025 was $100.00K, a 87.33% decline from fiscal 2024.
- CRESCENT BIOPHARMA, INC. operating lease, payments for fiscal 2024 was $789.18K, a 22.46% decline from fiscal 2023.
- CRESCENT BIOPHARMA, INC. operating lease, payments for fiscal 2023 was $1.02M, a 7.84% decline from fiscal 2022.
- CRESCENT BIOPHARMA, INC. operating lease, payments for fiscal 2022 was $1.10M, a 2.50% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-02-26 | ||||
| 2025-03-31 | $67.40K 10-Q · filed 2025-05-14 | $267.64K derived: sum of 2 quarters · filed 2025-05-14 | $463.95K derived: sum of 3 quarters · filed 2025-05-14 | $660.27K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-12-31 | $200.24K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $396.55K derived: sum of 2 quarters · filed 2025-02-13 | $592.87K derived: sum of 3 quarters · filed 2025-02-13 | $789.18K 10-K · filed 2025-02-13 | |
| 2024-09-30 | $196.31K 10-Q · filed 2024-11-13 | $392.63K derived: sum of 2 quarters · filed 2024-11-13 | $588.94K 10-Q · filed 2024-11-13 | $761.38K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-06-30 | $196.31K 10-Q · filed 2024-08-08 | $392.63K 10-Q · filed 2024-08-08 | $565.07K derived: sum of 3 quarters · filed 2025-05-14 | $850.19K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-03-31 | $196.31K 10-Q · filed 2025-05-14 | $368.75K derived: sum of 2 quarters · filed 2025-05-14 | $653.87K derived: sum of 3 quarters · filed 2025-05-14 | $934.39K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $172.44K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $457.56K derived: sum of 2 quarters · filed 2025-02-13 | $738.08K derived: sum of 3 quarters · filed 2025-02-13 | $1.02M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $285.12K 10-Q · filed 2024-11-13 | $565.64K derived: sum of 2 quarters · filed 2024-11-13 | $845.33K 10-Q · filed 2024-11-13 | $1.13M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $280.52K 10-Q · filed 2024-08-08 | $560.21K 10-Q · filed 2024-08-08 | $839.90K derived: sum of 3 quarters · filed 2024-08-08 | $1.12M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $279.69K 10-Q · filed 2023-05-03 | $559.38K derived: sum of 2 quarters · filed 2024-03-27 | $837.55K derived: sum of 3 quarters · filed 2024-03-27 | $1.11M derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-12-31 | $279.69K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $557.86K derived: sum of 2 quarters · filed 2024-03-27 | $831.54K derived: sum of 3 quarters · filed 2024-03-27 | $1.10M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $278.17K 10-Q · filed 2023-11-03 | $551.84K derived: sum of 2 quarters · filed 2023-11-03 | $824.71K 10-Q · filed 2023-11-03 | $1.10M derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-06-30 | $273.68K 10-Q · filed 2023-08-02 | $546.55K 10-Q · filed 2023-08-02 | $819.42K derived: sum of 3 quarters · filed 2024-03-27 | $1.09M derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-03-31 | $272.87K 10-Q · filed 2023-05-03 | $545.74K derived: sum of 2 quarters · filed 2024-03-27 | $817.12K derived: sum of 3 quarters · filed 2024-03-27 | $1.08M derived: sum of 4 quarters · filed 2024-03-27 | |
| 2021-12-31 | $272.87K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $544.25K derived: sum of 2 quarters · filed 2024-03-27 | $811.25K derived: sum of 3 quarters · filed 2024-03-27 | $1.08M 10-K · filed 2024-03-27 | $1.08B 10-K · filed 2022-03-03 |
| 2021-09-30 | $271.38K 10-Q · filed 2022-11-09 | $538.38K derived: sum of 2 quarters · filed 2022-11-09 | $804.60K 10-Q · filed 2022-11-09 | $1.07M derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-06-30 | $267.00K 10-Q · filed 2022-08-03 | $533.22K 10-Q · filed 2022-08-03 | $799.43K derived: sum of 3 quarters · filed 2023-03-29 | $1.06M derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-03-31 | $266.21K 10-Q · filed 2022-04-28 | $532.43K derived: sum of 2 quarters · filed 2023-03-29 | $797.19K derived: sum of 3 quarters · filed 2023-03-29 | $1.06M derived: sum of 4 quarters · filed 2023-03-29 | |
| 2020-12-31 | $266.21K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $530.98K derived: sum of 2 quarters · filed 2023-03-29 | $791.47K derived: sum of 3 quarters · filed 2023-03-29 | $1.05M 10-K · filed 2023-03-29 | |
| 2020-09-30 | $264.76K 10-Q · filed 2021-11-02 | $525.25K derived: sum of 2 quarters · filed 2021-11-02 | $784.98K 10-Q · filed 2021-11-02 | $941.11M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-06-30 | $260.49K 10-Q · filed 2021-08-05 | $520.21K 10-Q · filed 2021-08-05 | $940.84M derived: sum of 3 quarters · filed 2022-03-03 | $941.10M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-03-31 | $259.72K 10-Q · filed 2021-05-03 | $940.58M derived: sum of 2 quarters · filed 2022-03-03 | $940.84M derived: sum of 3 quarters · filed 2022-03-03 | $941.10M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2019-12-31 | $940.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $940.58M derived: sum of 2 quarters · filed 2022-03-03 | $940.84M derived: sum of 3 quarters · filed 2022-03-03 | $941.09M 10-K · filed 2022-03-03 | $941.09K 10-K · filed 2020-02-28 |
| 2019-09-30 | $259.01K 10-Q · filed 2020-11-06 | $514.51K derived: sum of 2 quarters · filed 2020-11-06 | $767.89K 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $255.49K 10-Q · filed 2020-07-31 | $508.88K 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | $253.39K 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |